Earnings

Average total degreed enrollment was 83,700 versus 81,900, an increase of 2.2% that the filing attributes primarily to improved student retention. The filing states that the increase in net revenue was partially offset by higher discounts, resulting from a higher percentage of enrollment through …

Labs revenue was USD 353 million, down 6%, primarily because of lower sales in China tied to recently announced changes to in vitro diagnostics pricing. Outside China, Labs revenue grew 3% as reported and 4% in constant currency. Immunohematology revenue was USD 142 million, …

Net revenues increased 7% including the currency headwind, mainly related to the U.S. dollar and Japanese yen. The increase in cars and spare parts was driven by product mix and higher personalizations, which surpassed 21% of total revenues from cars and spare parts and …

The quarter included two first-ever FDA approvals for gene therapies. Genglycos, an AAV8 therapy for glycogen storage disease type Ia, receivedAccelerated Approvalin August for patients aged eight and older, and Fayuvi, an AAV9 therapy for Sanfilippo syndrome type A, received standard full approval in …

The net loss was USD 17.7 million againstNet Incomeof USD 76.9 million. The company attributes the swing primarily to USD 79.1 million of share-based compensation expense for stock awards granted to full-time and part-time employees to commemorate its 50th anniversary, plus USD 6.9 million …

For the nine months ended September 30, 2026, net sales were USD 1,046,244 thousand versus USD 901,311 thousand, and gross profit was USD 569,075 thousand versus USD 482,864 thousand.

GAAP book value per common share declined 4.9% to USD 6.56 from USD 6.90, and the economic return on book value was negative 2.3%. ADividendof USD 0.18 per share was paid, the same as in the second quarter. Chief Executive Officer Christopher Abate said …